Breast cancer

Advanced HER2-positive/HER2-low breast cancer

Patient with brain metastasis and stable extracranial disease:  when to change antiHER2-based therapy
Patient with active brain metastasis: locoregional therapy vs systemic therapy
Patient with active brain metastasis:  T-DXd  vs.
tucatinib-based therapy
Can we use TDM1 after T-DXd 
Role of repeated biopsies to guide ADCs in HER2-low BC

Moderator:  Shereef Elsamany

Panel: 

Role of anthracyclines in early breast cancer

• When to omit anthracyclines in(neo) adjuvant therapy of HER2-negative breast cancer

  When to use anthracyclines in (neo) adjuvant therapy of HER2-positive breast cancer

Moderator:Dr. Meteeb Alfohaidi

Panel:

Satellite Symposium

Can we de-escalate axillary surgery/omit adjuvant radiotherapy with excellent response after NAC?

Complete response to NAC
Residual ITCs after NAC
Controversies of targeted axillary dissection
SLNB: Negative LNs in frozen section/positive in final pathology
Negative SLNB after neoadjuvant hormonal therapy

Moderator:Dr. Nasser Ali Al-Dhaibani Dr. Roaa Attieh

Panel:

Opening ceremony

Lunch & prayer

Satellite Symposium

Oncologists/pathologists dialogue TILS and descalation of systemic therapy in early breast cancer?

Moderator: Dr. Ahmed Alwbari Dr. Hatim Al Maghrabi

Genomic tools in breast cancer

•  chemotherapy in high risk lobular/mucinous BC?
• Neoadjuvant therapy in premenopausal patients with lobular BC?
  Adjuvant therapy with node negative and node positive lobular BC?
  Adjuvant therapy in luminal BC with RS 16-25?
  Can genomic tools guide adjuvant cdk4-6 inhibitors in N0/N1 tumours??
• Oncotype DX and selection of neoadjuvant  hormonal vs chemotherapy  therapy
• Role of interval Ki67 assessment with neoadjuvant  hormonal therapy

Moderator: Ahmed Alshehri

Panel: 

Break

Transition from hormonal-based to chemotherapy in metastatic BC??

• Patients with early progression on CDK4-6 inhibitors: What is next??
• When to start ADCs/olaparib in patients who had visceral crisis?? Can be upfront??
• Any role of hormonal monotherapy after CDK4-6 inhibitors??
• Biomarkers to guide subsequent therapies
• Can we use one ADC after previous ADC??

Moderator:  Dr. Ahmed Alfaraj

Panel:

Concluding remarks Day 1